Influenza picking up in U.S., predominantly A(H3N2)

December 8, 2017

(HealthDay)—Influenza activity was low during October 2017 but started increasing in November, with influenza A, predominantly A(H3N2), most commonly identified, according to research published in the Dec. 8 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Vivien G. Dugan, Ph.D., from the CDC in Atlanta, and colleagues summarized U.S. during Oct.1 to Nov. 25, 2017.

The researchers note that influenza activity was low during October 2017 in the United States, but since the start of November, activity has been increasing. The most commonly identified viruses have been influenza A viruses, with influenza A(H3N2) predominating. Several indicators of influenza activity were reported to be higher than normally seen at this time of year. Most influenza viruses characterized during this period were genetically or antigenically similar to the Northern Hemisphere cell-grown vaccine reference viruses for 2017 to 2018. Currently circulating viruses seem not to have undergone significant antigenic drift; circulating A(H3N2) viruses are antigenically less similar to egg-grown A(H3N2) viruses used for most U.S. influenza vaccine production. Hospitalizations and deaths were more common and was lower in recent past seasons in which A(H3N2) viruses predominated; it is unclear which influenza viruses will predominate in the 2017 to 2018 season.

"Vaccination should continue to be offered as long as are circulating and unexpired vaccine is available," the authors write.

One author disclosed holding two patents relating to influenza vaccines.

Explore further: H3N2 mutation in last year's flu vaccine responsible for lowered efficacy

More information: Abstract/Full Text

Related Stories

H3N2 mutation in last year's flu vaccine responsible for lowered efficacy

November 6, 2017
The low efficacy of last year's influenza vaccine can be attributed to a mutation in the H3N2 strain of the virus, a new study reports. Due to the mutation, most people receiving the egg-grown vaccine did not have immunity ...

CDC: Influenza vaccine 48 percent effective overall

February 20, 2017
(HealthDay)—This year's influenza vaccine is a fairly good match for the circulating viruses, according to research published in the Feb. 17 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality ...

Tough flu season ahead: vaccine may only be 10% effective

December 6, 2017
(HealthDay)—There's bad news about this year's flu vaccine.

Experts discuss Influenza vaccine challenges and opportunities

November 30, 2017
In a New England Journal of Medicine perspective, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the World Health Organization (WHO) Collaborating ...

Team develops new broadly protective vaccines for H3N2 influenza

November 2, 2017
A collaborative research and development partnership between researchers at the University of Georgia and Sanofi Pasteur, the largest influenza vaccine manufacturer in the world, has resulted in the identification of a vaccine ...

Pace of influenza activity picking up across the US

January 15, 2017
(HealthDay)—The pace of flu activity continues to quicken across the United States, and probably hasn't peaked yet, according to an assessment by the U.S. Centers for Disease Control and Prevention.

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.